| Literature DB >> 29035356 |
Rui-Hua Xu1, Wei Wei1,2, Michal Krawczyk2, Wenqiu Wang2, Huiyan Luo1,2, Ken Flagg2, Shaohua Yi2, William Shi2, Qingli Quan3, Kang Li3, Lianghong Zheng4, Heng Zhang5, Bennett A Caughey2, Qi Zhao1, Jiayi Hou2, Runze Zhang2, Yanxin Xu3, Huimin Cai3,4, Gen Li3,4, Rui Hou4, Zheng Zhong2, Danni Lin2, Xin Fu2, Jie Zhu2, Yaou Duan2, Meixing Yu3, Binwu Ying6, Wengeng Zhang3, Juan Wang7, Edward Zhang2, Charlotte Zhang2, Oulan Li2, Rongping Guo1, Hannah Carter2, Jian-Kang Zhu5, Xiaoke Hao7, Kang Zhang2,3,8.
Abstract
An effective blood-based method for the diagnosis and prognosis of hepatocellular carcinoma (HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying cancer-specific genetic and epigenetic aberrations may enable a noninvasive 'liquid biopsy' for diagnosis and monitoring of cancer. Here, we identified an HCC-specific methylation marker panel by comparing HCC tissue and normal blood leukocytes and showed that methylation profiles of HCC tumour DNA and matched plasma ctDNA are highly correlated. Using cfDNA samples from a large cohort of 1,098 HCC patients and 835 normal controls, we constructed a diagnostic prediction model that showed high diagnostic specificity and sensitivity (P < 0.001) and was highly correlated with tumour burden, treatment response, and stage. Additionally, we constructed a prognostic prediction model that effectively predicted prognosis and survival (P < 0.001). Together, these findings demonstrate in a large clinical cohort the utility of ctDNA methylation markers in the diagnosis, surveillance, and prognosis of HCC.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29035356 DOI： 10.1038/nmat4997
Source DB: PubMed Journal: Nat Mater ISSN： 1476-1122 Impact factor: 43.841